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Abstract
Haptoglobin is an acute phase inflammatory marker. Its main function is to bind hemoglobin released from erythrocytes to
aid its elimination, and thereby haptoglobin prevents the generation of reactive oxygen species in the blood. Haptoglobin
levels have been repeatedly associated with a variety of inflammation-linked infectious and non-infectious diseases,
including malaria, tuberculosis, human immunodeficiency virus, hepatitis C, diabetes, carotid atherosclerosis, and acute
myocardial infarction. However, a comprehensive genetic assessment of the inter-individual variability of circulating
haptoglobin levels has not been conducted so far. We used a genome-wide association study initially conducted in 631
French children followed by a replication in three additional European sample sets and we identified a common single
nucleotide polymorphism (SNP), rs2000999 located in the Haptoglobin gene (HP) as a strong genetic predictor of circulating
Haptoglobin levels (Poverall= 8.1610
259), explaining 45.4% of its genetic variability (11.8% of Hp global variance). The
functional relevance of rs2000999 was further demonstrated by its specific association with HP mRNA levels (b= 0.2360.08,
P= 0.007). Finally, SNP rs2000999 was associated with decreased total and low-density lipoprotein cholesterol in 8,789
European children (Ptotal cholesterol= 0.002 and PLDL= 0.0008). Given the central position of haptoglobin in many
inflammation-related metabolic pathways, the relevance of rs2000999 genotyping when evaluating haptoglobin
concentration should be further investigated in order to improve its diagnostic/therapeutic and/or prevention impact.
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Introduction
Human haptoglobin (Hp) is an acute phase inflammatory
glycoprotein essentially synthesized by the liver and up-regulated
by cytokines [1]. Hp is polymorphic with two co-dominant alleles,
Hp1 and Hp2 encoded by the Haptoglobin (HP) gene located in
chromosome 16 and resulting in three common isoforms: Hp1-1,
Hp2-2 and Hp2-1 (called HP ‘common polymorphism’) [2]. In
normal physiological conditions, Hp protein concentration in
blood ranges between 0.3 and 2.0 g/L in adults [3] but significant
fall in its level during the first decade of life [4]. The main property
of Hp is to scavenge circulating hemoglobin (Hb) released by
hemolysis or normal red blood cells turnover [5]. The resulting
circulating Hp-Hb complexes are eliminated by Kupffer’s cell(s) in
the liver, preventing the generation of reactive oxygen species
[2,6]. Therefore, Hp plays an important role in preventing renal
damage and iron loss that can occur following an intravascular
hemolysis. Hp is also able to bind apolipoprotein (Apo) A-I [7] to
protect the Apo A-I effector domain of lecithin-cholesterol
acyltransferase against oxidative stress, and Hp consequently
modulates the high-density lipoprotein (HDL) function [8].
Furthermore, Hp can bind Apo E and the resulting complexes
influence cholesterol esterification [9]. These functional charac-
teristics confer to Hp a major role in the reverse transport of
cholesterol between peripheral cells and the liver for degradation.
Hp levels and HP rs72294371 ‘common polymorphism’ (Data
S1) have been consistently associated with inflammatory-linked
infectious [10,11] and non-communicable diseases [11,12].
Malaria caused by Plasmodium falciparum, which is associated with
extensive intravascular hemolysis, decreases Hp to undetectable
levels as the Hb-scavenging system is saturated [13].13 In malaria-
endemic areas, hypohaptoglobinemia has been proposed as an
indirect biochemical indicator of malaria [14]. HP ‘common
polymorphism’ should be considered at diagnosis of tuberculosis.
Eisaev and colleagues [15] described an increased recurrence of
pulmonary tuberculosis with worse prognosis in Hp2-2 Cauca-
sians. Furthermore, this HP ‘common polymorphism’ contributes
to mortality and viral load in Human immunodeficiency virus
(HIV) infection [16]. Hp2-2 HIV carriers have a more
pronounced viral replication rate and a worse prognosis compared
to Hp1-1 or Hp2-1 HIV carriers [16,17]. Hepatitis C infection has
also been associated with low serum Hp concentrations [18] and
an overrepresentation of the Hp1-1 phenotype has been associated
with high risk for chronic hepatitis C [19,20]. The HP ‘common
polymorphism’ has also an effect on various other infectious
diseases [21,22,23,24].
In Type 2 diabetes patients, the Hp2-2 phenotype has been
suggested to confer greater risk of cardiovascular events [12,25,26]
and of carotid atherosclerosis [27]. Moreover, high Hp level is a
risk factor for acute myocardial infarction, stroke and heart failure
[28,29]. Therefore, the routine measurement of Hp level has been
suggested to be incorporated in daily medical practice to evaluate
cardiovascular risk [29].
Despite these findings, the basis of Hp level inter-individual
variability is still unknown. To identify genetic variants modulating
physiological levels of Hp, we analyzed genome-wide association
study (GWAS) data generated in European children for whom no
age-related disease may influence Hp concentrations. We also
assessed the association between the identified variants and
cardiovascular risk factors (total, HDL and low density lipopro-
tein-cholesterol, Apolipoproteins A1 and B).
Results
Table 1 shows the phenotypic characteristics of the studied
populations. Hp levels in children were low, in accordance with its
reference distribution [4].
Patterns of family correlations for serum Hp concentrations
were assessed following both unadjusted values (Table 2). Model 1,
which was not adjusted, did not show any family correlation.
Model 2, which took into account age and body mass index (BMI)
as covariates showed significant correlations for all the various
pairs of relatives. Model 3, which hypothesized no effect of gender
on family correlations, showed significant father-mother, father-
son and son-son correlations (Table 2).
We then assessed the components of variance attributable to
additive genetic effects, shared household effects and residual
environmental factors (including assay variability) in 656 nuclear
bi-parental families (2,680 individuals) from the STANISLAS
Family Study (SFS) cohort (Table 3). Model 2, which included the
three components after adjustment for age and BMI gave a better
description of the variance decomposition than model 1 which was
Table 1. Phenotypic characteristics of the studied populations.
Population Subsample
Sample size
(% female)
Age (years)
[95% CI]
BMI (kg/m2)
[95% CI]
Haptoglobin
(g/L) [95% CI]
LDL-
cholesterol
(mmol/L)
[95% CI]
Total cholesterol
(mmol/L) [95% CI]
SFS Discovery cohort:
Phase 1 vs Hp
631 (50.9%) 11.93 [11.76–
12.11]
17.66 [17.49–17.84] 0.65 [0.62–0.68] 2.99 [2.94–3.05] 4.79 [4.74–4.85]
Families: Phase 2 vs
Hp and lipids
2,957 (49.2%) 29.84 [29.38–
30.30]
22.66 [22.52–22.81] 0.95 [0.94–0.97] 3.43 [3.40–3.46] 5.30 [5.26–5.34]
Obese children Replication cohort:
Phase 2 vs Hp and lipids
1,015 (52.3%) 11.07 [10.86–
11.27]
28.24 [27.84–28.64] 1.18 [1.15–1.22] 2.74 [2.70–2.79] 4.47 [4.42–4.52]
GENDAI Replication cohort:
Phase 2 vs Hp and lipids
419 (53.1%) 11.16 [11.10–
11.23]
19.76 [19.46–20.07] 0.81 [0.76–0.85] 3.12 [3.06–3.17] 4.79 [4.73–4.86]
NFBC1986 Replication cohort: Phase 2 vs lipids 5,310 (50.8%) 16 21.27 [21.17–21.37] NA 2.54 [2.52–2.56] 4.27 [4.24–4.29]
VERONA cohort Replication cohort: Phase 2 vs lipids 401 (43.4%) 10.90 [10.75–
11.04]
18.01 [17.78–18.23] NA 2.41 [2.40–2.47] 4.21 [4.15–4.28]
CI: confidence interval; BMI: body mass index; LDL: low-density lipoprotein.
doi:10.1371/journal.pone.0032327.t001
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not adjusted. Hp genetic variance represented 26% (P,0.001) of
the total variance. Shared (i.e. within families) and random
environmental variances were 11.6 and 62.4% respectively
(Table 3).
Our GWAS based on 631 unrelated children of the SFS cohort
showed strongest association signal for Hp levels in a 218-kb
linkage disequilibrium (LD) block on chromosome 16 that includes
the HP gene (Figure 1). Using the square-root transformed Hp
measurement adjusted for gender, age and z-BMI under the
additive model, we identified in this region two significant
association signals 90-kb apart: rs2000999 (with A as allele effect:
b=20.123, standard error [SE] = 0.017, P=6.32610213;
Table 4) and rs10492825 (with C as effect allele: b=20.0876,
SE= 0.016, P=5.50610208; Table 4). Both SNPs rs2000999 and
rs10492825 display moderate LD (r2 = 0.48, HapMap CEU
release #27). In order to assess the redundancy between these
two signals, we ran conditional regression analyses for both SNPs
adjusted for each other and found that rs2000999 alone drove the
association observed at the HP locus (rs2000999: Prs10492825
adjusted=1.95610
27, rs10492825: Prs2000999 adjusted=0.91, Data S2,
Table S1).
We confirmed the association between SNP rs2000999 and
circulating Hp levels in three additional independent European
cohorts: the GENDAI study of Greek children, a subset of obese
children from the East of France (Ntotal=1,434), and a familial
subset (Ntotal=2,957) of the SFS cohort (Preplication=3.49610
241,
Poverall=8.09610
259; Table 4).
Table 2. Estimates of familial correlations 6 standard error for serum haptoglobin concentration (656 familles/2680 individuals).
Model 1 Model 2 Model 3 Model 4
Adjustment for None Age & BMI Age & BMI Age, BMI & rs2000999 allelic frequency
Father - Mother (FM) 0.12660.038 0.11160.038** 0.11160.038** 0.15660.038***
Father - Son (FS) 0.27760.037 0.26460.037*** 0.23060.021*** 0.20660.022***
Father - Daughter (FD) 0.27760.036 0.26560.037*** [0.230] [0.206]
Mother - Son (MS) 0.22760.036 0.20460.037*** [0.230] [0.206]
Mother - Daughter (MD) 0.18460.039 0.18860.040*** [0.230] [0.206]
Son - Son (SS) 0.21360.060 0.18660.064** 0.27460.036*** 0.23960.036***
Son - Daughter (SD) 0.27360.047 0.27160.047*** [0.274] [0.239]
Daughter - Daughter (DD) 0.35560.067 0.38660.064*** [0.274] [0.239]
Loge L
2 (Logarithm of likelihood function) 1458.83 1338.20 1342.20 1215.13
Alternate model Model 1 Model 2 Model 3
x2 (df) 241.26(8) 8.00(5) 254.14(4)
P *** NS ***
* P#0.05, ** P#0.01, *** P#0.001: compared to zero.
Model 1 estimated all eight correlations without adjustment.
Model 2 estimated all eight correlations with adjustment for age and BMI,
Model 3 estimated three correlations with adjustment for age and BMI with no gender effect on parent or offspring correlations: FS =MS=MD=FD and SS = SD=DD.
Model 4 estimated three correlations with adjustment for age, BMI and rs2000999 allelic frequency with no gender effect on parent or offspring correlations:
FS =MS=MD= FD and SS = SD=DD.
Values in brackets were constrained to be equal to a preceding value according to the hypotheses of the model.
BMI: body mass index.
doi:10.1371/journal.pone.0032327.t002
Table 3. Variance components of serum haptoglobin concentrations (656 families/2680 individuals, rs2000999 & rs4788597 as
allelic frequency).
Model 1 Model 2 Model 3
Adjustment for None Age & BMI Age, BMI & rs2000999 allelic frequency
Polygenic variance: s2G 0.047860.0120***, 24.9% 0.046060.0109***, 26.0% 0.022660.0101*, 14.2%
Household variance: s2H 0.025060.0065***, 13.0% 0.020660.0059***, 11.6% 0.023360.0053***, 14.7%
Residual variance: s2E 0.119460.0078***, 62.1% 0.110360.0072***, 62.4% 0.113060.0069***, 71.1%
Loge L
2 (Logarithm of likelihood function) 2968.90 21074.58 21200.04
Alternate model - Model 1 Model 2
x2 (df) - 211.36 (8) 250.92 (4)
P - *** ***
*P#0.05,
**P#0.01,
*** P#0.001.
BMI: body mass index.
doi:10.1371/journal.pone.0032327.t003
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Accounting for the rs2000999 allelic frequency, the pattern of
familial correlation (Table 2, model 4) decreased from 0.230 to
0.206 and from 0.274 to 0.239 for sibling and child-parent
respectively, whereas the adequacy of the model was significantly
improved. Additional adjustment for rs2000999 for the compo-
nents of variance attributable to additive genetic effects, shared
household effects and residual environmental factors (Table 3,
model 3) significantly improved the likelihood function and the
proportion of phenotypic variability accounted for by genetic
effects decreased (26.0% to 14.2%, in comparison to model 2).
Moreover, the component attributable to household factors
increased (11.6% to 14.7%). We thus determined that rs2000999
is the major genetic determinant of Hp levels accounting for
11.8% of Hp global variance and 45.4% of the genetic variance of
this trait.
In order to assess the degree of independence of rs2000999 from
the HP rs72294371 ‘common polymorphism’ (Data S1), we
genotyped the latter in the GWAS first stage children (SFS cohort)
Figure 1. Manhattan plot of the GWAS of the discovery cohort comprising 631 children. A, A Manhattan plot showing the 2log10(P
values) of SNPs from the association analysis of the 631 SFS children from stage 1. B, An overview of the 2log10(P values) of Chromosome 16. C, The
genomic region of the 618 LD block displayed in UCSC Genome Browser.
doi:10.1371/journal.pone.0032327.g001
Table 4. Discovery and replication of rs2000999 association data for Hp levels.
Haptoglobin (g/
L)
Population Stage N MAF GG GA AA b
Standard
error raw P
P adjusted with
rs10492825
SFS - unrelated children Discovery 631 0.21 0.73660.406 0.53260.321 0.36160.180 20.123 0.017 6.32610213 1.95610207
SFS - families Replication 2,957 0.20 1.05660.467 0.81960.445 0.54960.330 20.138 0.007 1.17610275
Obese children Replication 1,015 0.22 1.26160.492 1.06460.455 1.00260.534 20.088 0.013 1.20610211
GENDAI Replication 419 0.25 0.81160.450 0.81360.558 0.73160.319 20.021 0.021 0.306
Replication sample Replication 4,391 0.22 3.49610241
Overall meta-analysis Replication 5,022 8.09610259
N: sample size; MAF: Minor Allele Frequency; b:beta coefficient for the effect allele A.
doi:10.1371/journal.pone.0032327.t004
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by using a PCR-based method and a gel reading. Only a subset of
341 out of 631 samples was successfully genotyped after
independent readings by two readers. In this sample set, we found
no evidence for LD between HP ‘common polymorphism’ and
rs2000999 (r2 = 0.135) nor with the other SNPs that were
genotyped by the Illumina array within the 218 kb LD block that
includes both HP ‘common polymorphism’ and rs2000999
(0.001,r2,0.137; N=31 SNPs). Furthermore, the HP ‘common
polymorphism’ (minor allele frequency [MAF]= 0.46) and
rs2000999 (MAF=0.20) were both highly associated with Hp
levels, as expected (P=461027 and P=161027, respectively).
When both variants were included in the same regression model,
we found that they significantly and independently contributed to
the increased Hp levels (PHP rs72294371 ‘common polymorphism’=0.001 and
Prs2000999=5610
25) indicating that the association with rs2000999
would be novel and not redundant with the HP ‘common
polymorphism’. However, it is noteworthy that despite strong
efforts, we did not succeed by far in genotyping all samples. We
used two other technologies: a pre-designed TaqMan copy
number assay (Applied Biosystems) and a PCR-based method
with another design than previously used. Unfortunately, we did
not find a good concordance (,70%) between the three methods.
We conclude that given the state of art, we cannot definitively
conclude that the present signal of association is not related to the
HP ‘common polymorphism’ genotype.
In order to validate our main results, we secondary assessed the
effect of SNP rs2000999 on HP gene expression in subcutaneous
adipose tissue sample from 194 non-obese subjects ascertained
from the Swedish SibPair cohort (Data S2). We found a significant
contribution of rs2000999 to HP expression (b=0.2360.08;
P=0.007; PBayesian=0.006).
We finally assessed by additive model the effect of SNP rs2000999
on total, HDL and low-density lipoprotein (LDL) cholesterol,
Apolipoproteins A1 and B in five independent European pediatric
cohorts totaling 8,789 children. Total cholesterol was ln-trans-
formed and we normalized the LDL cholesterol by computing the
square root. All measurements were adjusted for gender, age
(excepting the NFBC1986) and z-score BMI. Our data showed that
rs2000999, with A as allele effect, was associated with total
cholesterol (b=20.011, SE=0.003, P=0.002; Table 5) and
LDL-cholesterol (b=20.017, SE=0.004, P=0.0008; Table 5).
The association with HDL-cholesterol and Apolipoproteins A1 and
B are displayed in Table S2.
Discussion
We first determined in 656 nuclear families that 26% of the Hp
plasma level variance was under genetic control. Then, using a
GWAS in 631 children from the same population and replicating
in three independent populations, we identified rs2000999 as the
major genetic determinant of Hp levels. This genetic variant alone
explained 45.4% of the genetic variance of this trait (11.8% of Hp
global variance). SNP rs2000999 is located in the intronic region
of HP gene, in a region previously believed to be the HPR gene
(encoding the haptoglobin-related protein) which shares more than
90% nucleotide sequence homology with HP [30]. It is 17 kb apart
a duplication of 59 a chain amino acid residues resulting to an
intragenic duplication of 1.7 kb and which is known as the HP
‘common polymorphism’ [31].
Our study shows that SNP rs2000999 also modulated
expression levels of the Hp mRNA in human adipose tissue
suggesting that this SNP (or a SNP in very strong LD with this one)
is indeed functional. It is noteworthy that SNP rs2000999 has been
previously reported to associate with total cholesterol in 4,200
adults from the EUROSPAN consortium [32] and with both total
and LDL-cholesterol in 100,000 adults of European and non-
European ancestry [33]. Interestingly, we confirmed the effect of
this SNP on these lipid traits in European children.
Increased plasma levels of several inflammatory markers
correlate with higher incidence and prognosis of various
cardiovascular diseases [34,35,36,37]. Hp level measurement has
been recently shown to improve the predictive information for
major cardiovascular events [29]. As rs2000999 is also associated
with lipid levels, this marker links inflammation and cardiovascular
risk. It is noteworthy that the impact of rs2000999 association on
lipids occurs early in life and is consistent with previous findings
that the precursors of cardiovascular diseases originate in
childhood [38,39].
Interestingly, the effect of rs2000999 on Hp levels is more
important in our discovery cohort which includes healthy children
having low Hp concentration (0.65 g/L60.39). As shown in the
analyses for other diseases [40], the statistical power of GWAS can
be increased in healthy homogeneous controls.
In addition, the effect of aging and of the environment is
minimized in children. Then, by using healthy pediatric
populations, we were able to assess more accurately the effect of
the SNP rs2000999 on Hp levels.
We tried to assess the degree of independence between
rs2000999 and the HP ‘common polymorphism’. Three different
methods were evaluated to genotype the HP ‘common polymor-
phism’ in our whole GWAS sample set. Unfortunately, we found
no concordance between the three methods, which underlie a
major difficulty to carry out an accurate genotyping of this
polymorphism. Even if this difficulty was not clearly discussed and
not published to our knowledge, it is admitted in the scientific field
Table 5. Association of rs2000999 with lipid traits.
Total cholesterol LDL-cholesterol
N MAF b Standard error p-value b Standard error p-value
SFS children 1,644 0.202 20.003 0.008 0.73 0.0004 0.010 0.967
Obese Children 1,015 0.216 20.008 0.011 0.439 20.009 0.013 0.507
GENDAI 419 0.253 20.023 0.012 0.055 20.031 0.013 0.022
NFBC1986 5,310 0.186 20.013 0.004 0.002 20.022 0.006 8.96E-05
Verona Cohort 401 0.200 20.011 0.014 0.446 20.011 0.016 0.515
Overall meta-analysis 8,789 20.011 0.003 0.002 20.017 0.004 0.0008
N: sample size; MAF: Minor Allele Frequency; b:beta coefficient for the effect allele A.
doi:10.1371/journal.pone.0032327.t005
rs2000999 Associates with Inflammation
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32327
and it should also be present in the clinical diagnosis setting. In
contrast, SNP rs2000999 can be accurately and easily genotyped.
Our findings should be further replicated in non-European
adults, especially in those affected by infectious diseases. More
generally, rs2000999 should be assessed in cohorts of patients
affected by the large variety diseases associated with Hp levels. It is
not a trivial task, as Hp is a trait that has been infrequently
measured in cohorts used for genetic studies. Given the major
effect of rs2000999 on Hp gene expression and on Hp levels,
Mendelian randomization approach would be of interest to test
the causative effect of this SNP on infectious and non-
communicable phenotypes in order to assess its clinical relevance.
Materials and Methods
Ethics Statement
All the populations involved in the present study were recruited
in accordance with the latest version of the Declaration of Helsinki
for Ethical Principles for Medical Research Involving Human
Subjects. All participants and their parents gave a written
informed consent. Genetic studies protocols were approved by
the local ethics committees for the protection of subjects for
biomedical research: the Comite´ Consultatif de Protection des
Personnes dans la Recherche Biome´dicale (CCPPRB).
Study populations
The STANISLAS Family Study (SFS). The SFS is a 10-year
longitudinal survey involving 1,006 volunteer families of European
ancestry whose members were free of chronic disease
(cardiovascular or cancer) with recruitment taking place from
1993–95 [41]. The SFS samples and data are part of the Biological
Resources Centre (BRC) ‘‘Interactions Ge`ne-Environnement
en Physiopathologie CardioVasculaire’’ (IGE-PCV) in Nancy,
France. Genome-wide genotyping was performed on a subset of
631 unrelated children (mean age 11.93 years [11.76–12.11])
constituting the discovery cohort [42] after screening for latent
population substructure (Data S2). The 2,957 remaining
individuals after quality control were analysed in the replication
studies (mean age 29.84 [29.38–30.30]). Hp levels, BMI and the
cardiovascular risk traits including total, high density lipoprotein
(HDL) and low density lipoprotein (LDL)-cholesterol (calculated
by the Friedewald formula [43]), Apolipoprotein A1 and B were
available for all participants.
Obese Children. We studied obese children (defined as
BMI.97th percentile for age and sex according to a French cohort
[44]) ascertained from 449 nuclear families with at least one obese
offspring, recruited in the Paediatric Endocrine Unit of Jeanne de
Flandres Hospital of Lille, France or through a national media
campaign. We analyzed 1,015 children (mean age 11.07 years
[10.86–11.27]) for whom Hp, BMI, total, HDL and LDL-
cholesterol, Apolipoprotein A1 and B measurements were
available.
The GeNe and Diet Attica Investigation (GENDAI). The
GENDAI pediatric cohort was recruited from children living in
the Attica region of Greece [45]. From November 2005 to June
2006, 1,138 peri-adolescent children were recruited from
randomly selected elementary schools of Attica. We analyzed
419 children (mean age 11.16 years [11.10–11.23]) for whom Hp,
BMI, total, HDL and LDL-cholesterol, Apolipoprotein A1 and B
measurements were available.
The Northern Finland 1986 Birth Cohort (NFBC
1986). The NFBC1986 is a prospective birth cohort including
all Finnish mothers of European ancestry with children whose
expected date of birth fell between July 1, 1985 and June 30, 1986 in
the two northernmost provinces in Finland [46]. Clinical
examination at 15–16 years follow-up was conducted between
August 2001 and June 2002. All cohort members living in Finland
with known address (n= 9,215) were invited, and 6,798 participated
(74%). We analyzed 5,310 adolescents successfully genotyped in the
NFBC1986 cohort for whom BMI, total, HDL and LDL-
cholesterol, Apolipoprotein A1 and B measurements were available.
The Verona cohort. The Verona cohort consists of Italian
children recruited from the general population of Verona, Italy,
whose families were randomly chosen from the registry office
database of the town, and contacted by post. We analysed 401
children (mean age 10.90 years [10.75–11.04]) successfully
genotyped for whom at least BMI, total, HDL and LDL-
cholesterol, Apolipoprotein A1 and B measurements were
available.
The SibPair cohort. The SibPair cohort comprises 154
nuclear families (732 subjects) from Sweden, each containing an
obesity-discordant sib pair (at least 10 kg/m2 difference in BMI).
Gene expression and genetic variation were analysed in 194 non-
obese subjects from the SibPair cohort.
Genotyping
Genomewide genotypes were generated for the 631 unrelated
SFS children using the Illumina Human CNV370-Duo array [42].
Briefly,750 ng of genomic DNA was processed using Illumina’s
protocol for the BeadStation genotyping platform (Illumina),
followed by GenCall software analysis(Illumina) to automatically
cluster, call genotypes, and assign confidence scores using the
GenTrain clustering algorithm (Illumina). We discarded a total of
2,552 SNPs due to the following reasons: extreme Hardy-
Weinberg disequilibrium (P,0.001), low genotyping call rates
(,95%) or low minor-allele frequencies (,1%). We retained
318,237 SNPs for analysis. Genomic control lGC was 1.01.
We used the Applied Biosystems SNPlexTM technology to
replicate the association of genome-wide significant genetic
variants in the SFS replication set, obese children and GENDAI,
NFBC1986 and Verona cohorts.
SNPlex is based on the Oligonucleotide Ligation Assay (OLA)
combined with multiplex PCR target amplification and was
carried out as per the manufacturer’s instructions (http://www.
appliedbiosystems.com). Allelic discrimination was performed by
capillary electrophoresis analysis using an Applied Biosystems
3730xl DNA Analyzer and GeneMapper 3.7 software. Genotyp-
ing call rate was above 95% in all populations studied and genetic
variants were in HW equilibrium (p.0.001).
We used a PCR-based method [47] to genotype for the HP
‘common polymorphism’ in the 631 children of the discovery
cohort (SFS cohort) in order to determine any linkage disequilib-
rium with regard to genome-wide significant variants identified in
the analysis. Only genotypes that were concordant following a
double blind genotyping call by two independent readers were
retained for statistical analyses (N=341). Two additional geno-
typing methods for HP ‘common polymorphism’ were used in
order to validate the above-method: a custom TaqMan copy
number assay (Applied Biosystems) following the manufacturer’s
recommendations and another PCR-based method using the
following oligonucleotide primers : 59-CTCTCCTTTCTCCC-
TTCCTGTC-39 and 59-TTTATCCACTGCTTCTCATTGT-
39. We didn’t obtain correspondence between the banding
patterns and the Hp genotypes.
Haptoglobin measurement
Blood samples were collected between 8:00 and 9:00 am or
11:30 and 12:30 pm by venipeuncture after overnight fasting. Hp
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protein levels were measured in blood plasma samples by high
sensitivity immunophotometry analyses using the BNTMII Siemens
analyzer (Siemens, Marburg, Germany) and Siemens reagents and
following the manufacturer’s instructions.
Lipids measurements
Total cholesterol, HDL-cholesterol and apolipoproteins A1 and
B were assayed using enzymatic methods (AU640 [Olympus,
Watford, UK]) and LDL-cholesterol was calculated using the
Friedewald formula [43].
Statistical analyses
Heritability estimate of Hp levels in the SFS. Intra-
familial correlations were estimated by using maximum likelihood
techniques [48] with and without adjustment for covariates. This
statistical approach allowed adjustment for covariates within
models, simultaneously and separately for fathers, mothers, sons
and daughters. The significance of various familial correlations, or
sex and generation differences in correlations, was tested using the
log-likelihood ratio test. Correlations were computed under two
sets of hypotheses: gender effects on correlations for parents and
children and no gender effect for all correlations.
Variance component analysis was applied in order to assess the
relative contributions of genetic, common household factors and
individual specific environment in familial aggregation of serum
haptoglobin concentrations. The variable used to estimate
variance component was adjusted for age and BMI, separately
for fathers, mothers, sons and daughters. The analysis was
conducted by using a multivariate normal model for pedigree
analysis as described by Lange and colleagues [49,50]. with the
software FISHER, which also performed tests of goodness-of-fit of
the underlying multinormal distribution. The general model
assumed that the studied trait was the result of the sum of three
independent random components: a polygenic component (G)
representing additive genetic factors, household factors common
to individuals within a family (H) and unmeasured environmental
factors particular to an individual (including measurement error)
(E). These three components were assumed to be normally
distributed with mean equal to 0 and variance equal to s2G, s2H
and s2E, respectively.
The hypothesis of no polygenic component or no household
effect was checked by comparing a model including s2G, s2H and
s2E with a model including only s2H and s2E or s2G and s2E,
respectively. In addition, possible effects of covariates (age and
BMI) and genome-wide significant variants’ allelic frequency on
these variance components were tested.
Comparison of nested models was based on the likelihood ratio
criteria. Eventually, the best parsimonious model was selected.
The percentage contributions of the three components, additive
genetic factors (heritability), household factors and residual
environmental, to residual phenotypic variance (after adjustment
for covariates) were determined.
Genome-wide association and replication analyses. We
carried out genome-wide association and replication analyses on Hp
levels using linear mixed regression models under the additive
genetic model with one degree of freedom, adjusting for age, gender
and BMI and using PLINK [51]. The summary statistics were
combined in the meta-analyses (Data S2), using the inverse normal
method with equal weight for each population. In this method, P
values of each study are transformed into their inverse normal z
score and the weighted sum, over all studies, is compared to a
normal N (0, 1), provided the sum of squared weights equals 1. The
estimates of variants effects on Hp and their standard errors for each
separate analysis were combined in the meta-analysis using the
weighted inverse normal method, and the overall effect and its
confidence interval were estimated using the inverse variance
method implemented in the ‘meta.summaries’ function of the
R RMETA package (http://cran.r-project.org/web/packages/
rmeta/index.html). No major heterogeneity in effects was
observed (P,0.02). The same mixed model and the same
software were used to analyse the association of genetic variants
with lipid traits.
Gene-expression investigation. To investigate the effect of
genome-wide significant variants on gene expression (Data S2), we
used data from 194 non-obese individuals from the SibPair cohort
[52]. Gene expression data for HP was measured in subcutaneous
adipose tissue [53] from 347 siblings using the Affymetrix
Human U133 Plus 2.0 platform (208470_s_at and 208471_at,
respectively). DNA was isolated from peripheral blood and
genotypes were generated using Illumina 610-Quad arrays.
We used a linear mixed model (Pinheiro and Bates, 2000) to
assess association of SNPs with gene expression. Log-transformed
expression level was regressed on the random-effect term, which
accommodates the family pedigree structure, and on the fixed-
effect terms i.e. sex, age, BMI level and the SNP of interest
(recoded as 0 =AA; 1=AG; 2=GG according to an additive
model). Analysis was carried out using the R function lmer()
(package lme4) with p-values obtained from the t-statistic.
Significance of the fixed effects was further investigated in the
Bayesian set-up using the R function mcmcsamp() (package lme4)
that generates Monte Carlo Markov Chain samples from the
posterior distribution of the parameters of a linear mixed model.
The prior on the fixed effects parameters is taken to be locally
uniform while the prior on the variance-covariance matrices of the
random effects is taken to be the locally non-informative prior.
Based on 100,000 samples drawn from the posterior distribution,
we calculated the smallest p such that the (12p) credible interval
does not contain the value 0. This parameter was finally used to
assess the p-value obtained from the t-statistic: if smaller than p, it
was considered anticonservative and its value discarded.
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